u/ServeIllustrious3803

https://pmc.ncbi.nlm.nih.gov/articles/PMC8073983/

Here is a plain-language breakdown of what this schematic means. The left panel shows normal brain traffic: the locus coeruleus sends norepinephrine to the orbitofrontal cortex, the ventral tegmental area sends dopamine to deeper cortical layers, and the reticular thalamic nucleus uses GABA to quiet the mediodorsal thalamus. That keeps glutamate input to the superficial cortex moderate. The right panel shows chronic guanfacine treatment, where α2A adrenoceptors are downregulated in the LC, VTA, and OFC. These receptors normally suppress norepinephrine release, so losing them means more baseline norepinephrine and dopamine in the frontal cortex, including co-releasing terminals in superficial layers. The mediodorsal thalamus also sends a stronger glutamate signal to superficial layers, while the thalamic GABA gate stays unchanged. In practical terms, your prefrontal cortex gets more of the three chemicals it needs for stable attention and impulse control, making it easier to focus, filter distractions, and pause before acting, not react on autopilot. That sustained chemical boost is exactly why the drug helps ADHD symptoms improve over time (in theory, ymmv

https://www.nature.com/articles/s41380-026-03802-1

Abstract: Fear extinction and its persistence depend on epigenetic modifications, which can be potentiated by histone deacetylase inhibitors (HDACis). Butyrate (NaBu), a short-chain fatty acid and endogenous HDACi, promotes persistent fear extinction in rodent models by increasing histone acetylation in promoter regions of plasticity- and memory-related genes, thereby enhancing their transcription. To test translational relevance in humans, we conducted a six-arm randomized, triple-blind, placebo-controlled intervention study in 180 healthy participants who underwent a 3-day Pavlovian fear conditioning paradigm. Participants ingested a single dose of NaBu or placebo either before or after extinction learning, the duration of which was additionally manipulated by varying the number of learning trials. NaBu facilitated later retrieval of extinction memory after seven days, both when administered before or after extinction learning, but it did not prevent return of fear during a subsequent reinstatement test. Interestingly, NaBu’s effects were contingent on robust extinction learning, emerging only when participants had been exposed to a high number of trials. As no side effects were observed with acute administration of the current dose, these findings support investigating NaBu as a potential adjunct for enhancing extinction-based interventions, such as prolonged exposure therapy, in anxiety disorders.